Recent Events & Catalysts
BridgeBio Pharma, Inc. (BBIO) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months
SeekingAlpha · today
BridgeBio Pharma (NASDAQ:BBIO) Flashes Perfect Technical Score and Tight Breakout Setup
ChartMill · today
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $115
Benzinga · today
Wells Fargo Maintains Overweight on BridgeBio Pharma, Raises Price Target to $102
Benzinga · today
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
SeekingAlpha · 1d ago
BridgeBio Pharma Q2 EPS $(0.78) Misses $(0.59) Estimate, Sales $243.676M Beat $218.743M Estimate
Benzinga · 1d ago
Alnylam plunges as earnings deliver ‘one-two punch’
Yahoo · 12d ago
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?
Yahoo · 14d ago
SEC Filings (90 days)
Results of operations (earnings release), Financial statements and exhibits
Filed 2026-08-10 · 1d ago · Material
Other events, Financial statements and exhibits
Filed 2026-07-22 · 20d ago
Entry into a material agreement, Unregistered sales of equity securities, Material modification to rights of security holders, Amendments to articles or bylaws, Regulation FD disclosure, Financial statements and exhibits
Filed 2026-07-02 · 40d ago
Departure/appointment of directors or officers, Submission of matters to a vote of security holders, Financial statements and exhibits
Filed 2026-06-26 · 46d ago
Other events, Financial statements and exhibits
Filed 2026-05-27 · 76d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.